Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial

Alison M. Schram, Nicoletta Colombo, Edward Arrowsmith, Vivek Narayan, Kan Yonemori, Giovanni Scambia, Amelia Zelnak, Todd M. Bauer, Ning Jin, Susanna V. Ulahannan, Marco Colleoni, Philippe Aftimos, Mark T. A. Donoghue, Ezra Rosen, Vasilisa A. Rudneva, Melinda L. Telli, Susan M. Domchek, Matthew D. Galsky, Margaret Hoyle, Colombe ChappeyRoss Stewart, John A. Blake-Haskins, Timothy A. Yap

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Fingerprint

Entra nei temi di ricerca di 'Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial'. Insieme formano una fingerprint unica.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science